(Q38899873)

7 September 2017

1 reference

title

Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer (English)

1 reference

7 September 2017

Jiali Yang

1

1 reference

7 September 2017

Juan Chen

2

1 reference

7 September 2017

Jun Wei

3

1 reference

7 September 2017

Xiaoming Liu

4

1 reference

7 September 2017

William C Cho

5

1 reference

7 September 2017

language of work or name

English

0 references

publication date

18 July 2016

1 reference

Expert Opinion on Biological Therapy

7 September 2017

published in

1 reference

7 September 2017

volume

16

1 reference

7 September 2017

issue

10

1 reference

7 September 2017

page(s)

1209-1223

1 reference

Cancer statistics in China, 2015.

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

21 January 2018

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

BRCA1: a novel prognostic factor in resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Distant Metastases in Uterine Leiomyosarcomas: The Wide Variety of Body Sites and Time Intervals to Metastatic Relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Immune checkpoint therapy for non-small-cell lung cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Coinhibitory molecules in cancer biology and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Molecular cloning and characterization of the full-length cDNA encoding the porcine CD28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Reverse immunoediting: When immunity is edited by antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Immunotherapy for lung cancer: for whom the bell tolls?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Nivolumab for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Ipilimumab: its potential in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Clinical development of the anti-CTLA-4 antibody tremelimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Role of PD-1 in regulating T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

The role of the PD-1 pathway in autoimmunity and peripheral tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Immune checkpoint inhibitors in advanced nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Ipilimumab in patients with cancer and the management of dermatologic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Innate and adaptive immune cells in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

21 January 2018

PD-1/PD-L1 inhibitors.

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Combined Immune Checkpoint Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Combining immunotherapy and targeted therapies in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Cancer Neoantigens and Applications for Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1214265

10.1080/14712598.2016.1214265

21 January 2018

Identifiers

DOI

1 reference

release_fnwwfxm6avhorn5id6oipcocmm

7 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fnwwfxm6avhorn5id6oipcocmm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference